Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Novalar has received approval to market OraVerse (phentolamine mesylate injection) for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental anesthetic. In clinical trials, OraVerse reduced the median recovery time to normal sensation in the lower lip by 85 minutes and in the upper lip by 83 minutes compared to control. Within one hour after OraVerse administration, 41% of patients reported normal lower lip sensation as compared to 7% in the control group, and 59% of patients in the OraVerse group reported normal upper lip sensation as compared to 12% in the control group.
OraVerse is expected to launch in October 2008.
For more information call (858) 436-1100 or visit www.novalarpharm.com.
